心力衰竭患者利尿剂抵抗的发病机制与治疗进展

Pathogenesis and Treatment of Diuretic Resistance in Patients with Heart Failure

心力衰竭(HF)是各种原发或继发性心脏病的最终结局,是全世界的重大健康问题之一。控制钠摄入及使用利尿剂被普遍认为是HF的基本治疗方式,但有20%~50%的心力衰竭患者存在利尿剂抵抗(DR)。DR与HF患者心血管事件的风险增加、住院时间延长以及再入院有关。现概述HF患者中的DR现象,并全面总结其发病机制及治疗,旨在为临床医生及科研人员提供更全面、多维度的理解,促进对合并DR的HF患者的发病机制和治疗策略的深入探讨。

Heart failure(HF)is the ultimate outcome of various primary or secondary cardiac diseases and stands as a significant global health concern.Controlling sodium intake and using diuretics are widely recognized as fundamental therapeutic approaches for HF.However,approximately 20%to 50%of HF patients experience diuretic resistance(DR).DR is associated with an increased risk of cardiovascular events,prolonged hospitalization,and readmission in HF patients.This review aims to outline the phenomenon of DR in HF patients,comprehensively summarizing its pathogenesis and treatment.It is intended to provide clinicians and researchers with a more comprehensive and multidimensional understanding,promoting in-depth discussions on the pathogenesis and treatment strategies for HF patients with DR.